Resonant X-ray emission spectroscopy of platinum(ii) anticancer complexes
- 18 January 2016
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 141 (4) , 1226-1232
Abstract
Platinum-based drugs are commonly used in cancer treatment. The biological activity of a metallodrug is obviously closely related to its chemical and stereochemical characteristics. An overlooked aspect is the effect of the ligand to the electronic structure of the metal atom (coordinated atom). We report herein a Resonant X-ray Emission Spectroscopy (RXES) study on the chemical speciation of chiral platinum complexes in which diastereomers are distinguished on the basis of their metal electronic configuration. This demonstrates RXES high chemical speciation capabilities, a necessary property to further investigate the reactivity of the Pt atom towards nucleophiles or bionucleophiles, and an important complement the previously reported RXES abilities, namely that it can be employed for in situ studies at physiological concentrations.Keywords
This publication has 35 references indexed in Scilit:
- Pt-based drugs: the spotlight will be on proteinsMetallomics, 2014
- The interaction of cisplatin with a human telomeric DNA sequence containing seventeen tandem repeatsBioorganic & Medicinal Chemistry Letters, 2013
- The status of platinum anticancer drugs in the clinic and in clinical trialsDalton Transactions, 2010
- Metal based drugs: from serendipity to designDalton Transactions, 2007
- The resurgence of platinum-based cancer chemotherapyNature Reviews Cancer, 2007
- Theoretical Study of Cisplatin Binding to Purine Bases: Why Does Cisplatin Prefer Guanine over Adenine?Journal of the American Chemical Society, 2003
- Cisplatin: mode of cytotoxic action and molecular basis of resistanceOncogene, 2003
- Basis for recognition of cisplatin-modified DNA by high-mobility-group proteinsNature, 1999
- NMR Solution Structure of a DNA Dodecamer Duplex Containing a cis-Diammineplatinum(II) d(GpG) Intrastrand Cross-Link, the Major Adduct of the Anticancer Drug CisplatinBiochemistry, 1998
- X-Ray Structure of the Major Adduct of the Anticancer Drug Cisplatin with DNA: cis -[Pt(NH 3 ) 2 {d(pGpG)}]Science, 1985